• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MICRO THERAPEUTICS, INC. DBA EV3 AXIUM; DEVICE, NEUROVASCULAR EMBOLIZATION

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MICRO THERAPEUTICS, INC. DBA EV3 AXIUM; DEVICE, NEUROVASCULAR EMBOLIZATION Back to Search Results
Model Number UNK-NV-AXIUM
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Muscle Weakness (1967)
Event Date 07/30/2014
Event Type  Injury  
Manufacturer Narrative
Alurkar a, karanam lsp, oak s, nayak s.Endovascular treatment of fusiform a2 aneurysm with parent artery occlusion.Surgical neurology international.2014;5(suppl 4):s199-s202.Doi:10.4103/2152-7806.137752 b.3.Please note that this date is based off of the date of publication of the article as the event dates were not provided in the published literature.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Alurkar a, karanam lsp, oak s, nayak s.Endovascular treatment of fusiform a2 aneurysm with parent artery occlusion.Surgical neurology international.2014;5(suppl 4):s199-s202.Doi:10.4103/2152-7806.137752 medtronic literature review found a report of patient complications in association with 5 axium coils and an echelon 10 microcatheter.The purpose of this article was to present a case of endovascular parent artery occlusion treatment of a ruptured fusiform a2 or proximal pericallosal artery aneurysm in a 32-year-old female who presented with subarachnoid hemorrhage.Endovascular coil occlusion along with the parent artery was planned.The article does not state any technical issues during use of the axium coils or echelon 10 microcatheter.The following intra- or post-procedural outcomes were noted: -post-procedure angiogram showed complete exclusion of the aneurysm from the circulation with parent artery sacrifice and the distal aca territory was seen filling via the pial collaterals from the middle cerebral artery.On extubation, the patient developed weakness of right lower limb (power = 2/5).She was then kept on dopamine infusion to achieve mean arterial pressure (map) of >90 mm hg in order to maintain adequate cerebral blood perfusion, thus facilitating good revascularization via good pial collaterals to retain distal aca supply.Her weakness improved completely over the next 24 hours and she was discharged on the 9th postoperative day.On 1 month clinical follow-up, she did not have any complaints and her neurological examination was normal.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
AXIUM
Type of Device
DEVICE, NEUROVASCULAR EMBOLIZATION
Manufacturer (Section D)
MICRO THERAPEUTICS, INC. DBA EV3
9775 toledo way
irvine CA 92618
Manufacturer (Section G)
MICRO THERAPEUTICS, INC. DBA EV3
9775 toledo way
irvine CA 92618
Manufacturer Contact
glen belmer
9775 toledo way
irvine, CA 92618
6122713209
MDR Report Key16056417
MDR Text Key306254678
Report Number2029214-2022-02196
Device Sequence Number1
Product Code HCG
Combination Product (y/n)N
Reporter Country CodeIN
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature,Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 12/27/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/27/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberUNK-NV-AXIUM
Device Catalogue NumberUNK-NV-AXIUM
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received12/19/2022
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Hospitalization;
Patient Age32 YR
Patient SexFemale
-
-